Capricor

Field throws stem cells for COVID-19 like spaghetti on the wall

Hype

The idea of testing stem cells for COVID-19 may be music to the ears of some folks as an opportunity, but to me from the beginning it sounded mostly like a spaghetti on the wall road to trouble. There is buzz out there that some kind of stem cells or other cells will help with …

Field throws stem cells for COVID-19 like spaghetti on the wall Read More »

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more

EM-of-Novel-Coronavirus-SARS-CoV-2-that-causes-COVID-19

  It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an …

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program

Capricor

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse …

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program Read More »

Upbeat prospects for some California clinical trial efforts from CIRM

Asterias-cells

Over at the California Stem Cell Report, David Jensen is reporting on some good news from CIRM for California on the stem cell clinical trial front. Stem cell biotechs Asterias and Capricor have stem cell trials supported by 20+ million in CIRM funding each and have been hitting milestones. These trials are progressing and so far have good safety …

Upbeat prospects for some California clinical trial efforts from CIRM Read More »

Interview with Robert Klein on CIRM’s Future

What does the future hold for CIRM? I asked former CIRM Board Chair and Prop 71 leader, Robert Klein, about that and more in the interview below. He also says some particularly exciting clinical trial and other developments in the stem cell field are coming soon. What got you excited for the very first time …

Interview with Robert Klein on CIRM’s Future Read More »

J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014

Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made …

J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014 Read More »